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Abstract 
A simple and sensitive ion chromatography method has been developed for the 
determination of cyclopropylamine (CPA) in nevirapine (NEV) and moxifloxacin 
HCl  (MOX) pharmaceutical drug substances. Efficient chromatographic 
separation was achieved on a Metrosep C4, 5 µm (250 mm x 4.0 mm) column. 
The mobile phase consists of 5 mM hydrochloric acid containing 10% (v/v) 
acetonitrile and was delivered in an isocratic mode at a flow rate of 0.9 mL 
min
−1  at 27°C. A  conductometric detector was used for the detection of  the 
analyte.  The drug substances were subjected to stress conditions including 
oxidation, thermal, photolytic and humidity for the evaluation of the stability-
indicating nature of the method. The method was validated for specificity, 
precision, linearity, accuracy and solution stability. The limit of detection (LOD) 
and limit of quantification (LOQ) values are 0.10 µg mL
−1 and 0.37 µg mL
−1 
respectively. The linearity range of the method is between 0.37 µg mL
−1 and 1.5 
µg mL
−1  and the correlation coefficient is found to be 0.9971. The  average 
recoveries of CPA in NEV and MOX are 97.0% and 98.0%, respectively. 78  P. K. S. R. Kothapalli et al.:   
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Introduction 
Nevirapine (NEV) is an antiretroviral drug, specifically a non-nucleoside reverse 
transcriptase inhibitor. It is used to treat HIV, a retrovirus, with excellent biodistribution and 
good potential for use in combination with other antiretrovirals across the spectrum of HIV 
disease as well as in selected populations [1]. The chemical name of nevirapine is 
11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one.  The 
molecular formula is C15H14N4O and the molecular weight is 266.30.  
Moxifloxacin is a new fourth-generation 8-methoxy-fluoroquinolone developed primarily for 
the treatment of community acquired pneumonia and upper respiratory tract infections. It is 
active against gram negative pathogens, gram positive cocci, aerobic intracellular bacteria, 
atypical organisms and anaerobic bacteria [2–3].  The chemical name of moxifloxacin 
hydrochloride (MOX) is 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-
pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride. The 
molecular formula is C21H24FN3O4 ⋅ HCl and the molecular weight is 437.90. Cyclopropyl-
amine (CPA) is used as raw material in synthetic process of NEV [4]. In this process, CPA 
is used to convert 2-chloro-N-(2-chloro-4-methylpyridin-3-yl)pyridine-3-carboxamide  into 
N-(2-chloro-4-methylpyridin-3-yl)-2-(cyclopropylamino)pyridine-3-carboxamide, and also in 
synthetic process of MOX [5].  
CPA is a primary amine and has not been listed in residual solvents category in any of the 
regulatory guidelines and pharmacopoeias [6–8]. CPA has been widely applied as 
mechanistic probes of cytochrome P450 enzymes and other oxidative enzymes [9]. With 
regard to toxicity, its oral LD50 value in rat is 445 mg/kg [10]. Other than this there is no 
toxicity literature available to the best of our knowledge. The determination of CPA by gas 
chromatography (GC) [11] has been reported in  literature.  Additional references are 
available for the determination of volatile amines in air/gas samples by GC, free volatile 
amines after solid-phase microextraction by capillary GC, and ammonia and methylamines 
in natural waters by flow injection gas diffusion coupled with ion chromatography [12–14]. 
But, to the best of our knowledge, no literature is available for the determination of CPA in 
pharmaceutical drug substances by ion chromatography. According to International 
Conference on Harmonization (ICH) guidelines on impurities [15], any impurity other than 
an active moiety should be controlled with suitable limits in the drug substance irrespective 
of its harmful nature, and the limit of such impurities are not more than 0.1% [16]. This 
research paper describes the stability-indicating nature of the method by performing the 
forced degradation studies to drug substances as an active moiety of both the drug 
substances include CPA group. The chemical structures of NEV and MOX are depicted in 
Fig 1, wherein the CPA group is marked by encircling.    Simple and Sensitive Stability-Indicating Ion Chromatography Method for the Determination …  79 
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Fig. 1.  The CPA group in the chemical structures of NEV and MOX 
Experimental 
Chemicals, reagents and samples 
CPA standard, samples of NEV, MOX drug substances and their related substances 
[17, 18], ethyl nevirapine [Ph.Eur impurity A], descyclopropyl nevirapine [Ph.Eur impu-
rity B],  n-propylnevirapine [Ph.Eur impurity C],  6,8-difluoro  [USP moxifloxacin related 
compound A or Ph.Eur impurity A], 6,8-dimethoxy [Ph.Eur impurity B], 8-ethoxy [Ph.Eur 
impurity C], 6-methoxy-8-fluoro [Ph.Eur impurity D] and 8-hydroxy [Ph.Eur impurity E] were 
gifted from APL Research Centre (A division of Aurobindo Pharma Ltd., Hyderabad, India). 
Analytical reagent (AR grade) hydrochloric acid, nitric acid, dipicolinic acid, sodium 
hydroxide, hydrogen peroxide, reagents, HPLC grade acetonitrile was purchased from E 
Merck, Mumbai, India. Highly purified water was obtained from millipore purification 
system (Millipore
®, Milford, MA, USA). Photo stability studies were carried out in a photo 
stability chamber (Make: Sanyo, Model: PSC062.AHA.C, Sanyo Gallenkamp PLC, Leics, 
UK).Thermal studies were carried out in thermal oven (Make: Newtronic, Model: NW-CON-
51, Mumbai, India) and humidity studies were carried out in humidity chamber (containing 
saturated aqueous solution of potassium nitrate by creating 90% relative humidity at 
25°C). 
Ion chromatography 
An ion chromatography system Metrohm 733 IC separation centre equipped with 732 
conductometric detector, 709 IC pump, 762 IC interface and Metrohm 813 compact auto 
sampler with Metrohm IC net 2.3 data handling system (Metrohm, Switzerland) was used. 
The mobile phase was a 5 mM hydrochloric acid containing 10% acetonitrile by volume. 
The analysis was carried out on Metrosep C4, 5 µm, 250 mm long, 4.0 mm i.d. column at 
27°C temperature. The mobile phase was delivered in an isocratic mode at a flow rate of 
0.9 mL min
−1. Detector scale range was 2 mS cm
−1 and full scale was 10 µS cm
−1.The 
thermostat temperature was set to 35°C and the conductivity flow cell constant was 16.3. 
The injection volume was 20 µL and the run time was 30 min. The retention time of the 
CPA peak is at about 5.2 minutes. The relative standard deviation for the peak areas of 80  P. K. S. R. Kothapalli et al.:   
Sci Pharm. 2012; 80: 77–87 
the six replicate injections for CPA peak was found to be less than 5.0%. This criterion has 
been used as system suitability criteria. 
Preparation of solutions 
Standard solution 
Accurately weigh and transfer 50 mg of CPA into a 100 mL volumetric flask containing 5 
mL of mobile phase and make up to the volume with mobile phase. Dilute this solution to a 
final concentration of 0.75 µg/ml with mobile phase. Filter the solution through 0.45 µ 
porous membrane. 
Sample solutions for NEV and MOX 
Prepare a concentration of 1500 µg/ml of sample solutions with respective diluents 
individually and filter these solutions through 0.45 µ porous membrane. 
Results and discussion 
Method development and optimization 
Based on column applications, for biogenic amines separation, Metrohm do suggest using 
C2 and C4 columns. Among these two columns, Metrosep C4 250 column is found to have 
excellent separation performance having a good column packing material (silica gel with 
carboxyl groups). Carboxyl groups in the stationary phase interact with analyte ions having 
opposite charge and lead to retain by the stationary phase. Therefore, the developmental 
work was started using this column. According to the application notes published by the 
Metrohm, mobile phase was prepared by mixing 1.7 mmol/L nitric acid and 0.7 mmol/L 
dipicolinic acid and using this mobile phase  the CPA, NEV and MOX solutions were 
prepared and injected into the system. In these trials, CPA peak response was good. 
However, there was comparatively more noise, and remarkably the peak elution time of 
nevirapine was more than 60 min and the peak of moxifloxacin was not eluted. Therefore, 
the mobile phase was modified with 5 mmol hydrochloric acid instead of nitric acid without 
the addition of dipicolinic acid. In this trial, response of CPA was good and base line noise 
was low. However, the retention time of NEV peak was the same with regard to the 
previous trial. To improve the peak shape of CPA, acetonitrile was added as an organic 
modifier to mobile phase in various ratios, and finally with the ratio of 90:10% v/v, we 
achieved good peak shape of CPA as well as shorter elution time of NEV peak (at around 
20 min). Then, the effect of concentration of hydrochloric acid was verified with 4 mmol, 
6 mmol and 8 mmol, and there was no effect of peak shape and elution time. In this mobile 
phase, there was no interference observed from NEV and MOX related substances peaks 
and also with other inorganic cations like lithium, sodium, ammonium, potassium, 
magnesium, calcium and amines like monomethylamine, ethylamine, dimethylamine, 
n-propylamine, ethylmethylamine, diethyl amine and triethylamine. For MOX, mobile phase 
was chosen as diluent, while for NEV, because of poor solubility of drug substance in 
mobile phase, 1:1% v/v mobile phase and acetonitrile was chosen as diluent. Moreover, 
during method optimization, we performed forced degradation experiments for both drug 
substances, and it was found that the CPA peak is specific. The forced degradation 
experiment details have been reported in the method validation section. 
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Method validation 
The developed and optimized method was validated as per the ICH guidelines [19], 
individually in terms of specificity, forced degradation studies (stability-indicating nature), 
sensitivity (limit of detection, limit of quantification), linearity, accuracy, precision and 
stability of sample solution. 
Specificity  
Specificity of the method was assessed by measuring the analyte response in the 
presence of all impurities related to drug substance. NEV and MOX related substances 
were spiked into sample solutions at pharmacopoeial levels [17, 18] along with and without 
CPA at about 500 µg/g in triplicate, and were injected into IC and determined the CPA 
content. The % difference between mean of CPA content in spiked individually and spiked 
with known related substances are 1.7 and 0.6 for  NEV and MOX, respectively. The 
specificity experimental results are given in table 1.  
Tab. 1.   Specificity of CPA 
S.No 
NEV  MOX 
Without 
spiking of 
related 
substances 
Spiked 
with 
related 
substances 
Without 
spiking of 
related 
substances 
Spiked with 
related 
substances 
CPA content (µg/g)  CPA content (µg/g) 
1  541  503  472  473 
2  515  515  462  460 
3  512  525  462  472 
Average  523  514  465  468 
SD  15.9  11.0  5.8  7.2 
RSD (%)  3.0  2.1  1.2  1.5 
% difference between 
spiked & unspiked  1.7  0.6 
 
Hence it was found that there was no interference observed in the determination of CPA 
content. Overlaid chromatograms of NEV spiked with all known related substances 
including CPA, NEV spiked with all known related substances excluding CPA, blank 
solution for NEV, MOX spiked with all known related substances including CPA, MOX 
spiked with all known related substances excluding CPA, blank solution for MOX with CPA 
standard solution are given in Fig 2(a) and in Fig 2(b) for NEV and MOX respectively. 82  P. K. S. R. Kothapalli et al.:   
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Fig. 2a.   Overlaid chromatograms of (a) NEV spiked with all known related substances 
including CPA, (b) blank solution for NEV, (c) NEV spiked with all known related 
substances excluding CPA and (d) CPA standard solution. 
 
 
Fig. 2b.   Overlaid chromatograms of (e) CPA standard solution, (f) blank solution for 
MOX (g) MOX spiked with all known related substances excluding CPA and (h) 
MOX spiked with all known related substances including CPA. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 min
-10
-8
-6
-4
-2
0
mV
ub172247
C
P
A
uc251917
uc261542
uc261803
a 
b 
c 
e 
f 
g 
   Simple and Sensitive Stability-Indicating Ion Chromatography Method for the Determination …  83 
Sci Pharm. 2012; 80: 77–87 
Also, the blank solutions spiked with all known related substances of NEV and 
MOXwithout spiking CPA were injected and the interference was evaluated. Moreover, the 
stability-indicating nature of the method was verified through the forced degradation/stress 
studies of drug substances as the drug substance active moieties contain the CPA group. 
In this study, NEV and MOX drug substances were subjected to the following stress 
conditions: 
  Thermal stress: The drug substances were subjected to dry heat at 105°C for 
120 h. 
  Stress study under photolytic condition (as per ICH) [20]: A sample was exposed to 
photolytic degradation (white fluorescent light (10K Lux/120 h followed by UV light 
200 watt-hours/m
2. 
  Stress study under humidity condition: A sample was exposed to degrade under 
90% RH at 25°C for 120 h. 
  Stress study under an oxidative condition: A sample solution was mixed with a 30% 
H2O2 solution and exposed to 85°C for 60 min. 
The unstressed samples and each stressed sample were prepared to the required 
concentration and injected into IC using the analytical conditions. In unstressed samples, 
the result of CPA content was found to be not detected and in each stressed sample, there 
was no peak observed at the retention time of CPA. Hence, based on the above 
observation, the stressed conditions did not induce the degradation of API leading to CPA. 
Therefore, this method is specific, selective and having stability-indicating nature. We have 
applied the same methodology for pharmaceutical formulations like NEV tablets and MOX 
tablets. But, this method was not specific with respect to placebo interference experiment 
for NEV tablets. However, for MOX tablets, no placebo interference was observed. 
Sensitivity (LOD and LOQ) 
Sensitivity of method was determined by establishing the limit of detection (LOD) and limit 
of quantification (LOQ) values based on the residual standard deviation of a regression 
line and slope. CPA standard solution was injected into ion chromatograph from lower 
concentration (0.1 µg mL
−1) to higher concentration (1.5 µg mL
−1). A plot of peak area 
(mV*sec) versus concentration (µg mL
−1) was drawn and LOD/LOQ values were predicted 
by STEYX (SD) and slope (S) method using the formula 3.3 x SD/S for LOD and 10 x 
SD/S for LOQ. The predicted concentration levels of LOD and LOQ solutions of CPA were 
verified for precision by analyzing six replicates.  The achieved précised values are 
presented in table 2. 
Linearity  
The linearity of the method was determined by taking the same data obtained in LOD/LOQ 
prediction. The linearity of conductometric detector response of CPA at different 
concentrations was studied in the range of LOQ level i.e. 0.37 to 1.5 µg mL
−1. The data 
was subjected to statistical analysis using a linear-regression model. The statistical 
parameters slope, intercept, STEYX and correlation coefficient values are calculated and 
shown in table 2. 84  P. K. S. R. Kothapalli et al.:   
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Tab. 2.   Statistical parameters obtained for CPA 
Statistical parameters  Results 
Correlation coefficient  0.9971 
Concentration range (µg mL
−1)  0.37–1.5 
Intercept  −0.377 
Slope (S)  9.207 
STEYX (SD)  0.343 
Limit of detection (µg mL
−1)  0.10 
Limit of quantification (µg mL
−1)  0.37 
Precision for Limit Of Detection RSD (%)  7.3 
Precision for Limit Of Quantification RSD (%)  2.7 
 
Accuracy  
Recovery of the method was carried out by spiking CPA to sample solutions in triplicate at 
three different levels at around 250, 500 and 750 µg/g, and the percentage recoveries 
were calculated. The average recovery values are reported in table 3. 
Tab. 3.   Recovery (%) values for CPA 
Accuracy (Average 
of 3 replicates)  Level-I  Level-II  Level-III  Overall recovery (%, 
Average of 9 replicates) 
  NEV   
Added (µg/g)  249.3  499.0  749.0 
97.0  Recovered (µg/g)  242.8  482.0  726.0 
Recovery (%)  97.4  96.6  96.9 
RSD (%)  0.9  1.3  1.6 
  MOX   
Added (µg/g)  252.7  505.0  757.0 
98.0  Recovered (µg/g)  249.7  492.3  739.0 
Recovery (%)  98.8  97.5  97.6 
RSD (%)  3.5  1.2  0.5 
 
Precision 
The precision of the system was checked by injecting six replicates of CPA standard 
solution in different days and achieved RSD (%) was below 5.0. The repeatability (method 
precision) and reproducibility (ruggedness) of the method was studied by analyzing six 
sample solutions separately by spiking CPA at about 500 µg/g level. The ruggedness of 
the method was defined as the degree of reproducibility obtained by the analysis of the 
same samples (which is used in the Method precision) under a variety of conditions using 
different  series of column, with different analysts on different days by preparing new 
standards and new mobile phase. Achieved results along with statistical data are given in 
table 4. 
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Tab. 4.  Statistical data of precision obtained for determination of CPA 
  NEV 
  Repeatability  
of standard
a 
Repeatability  
of sample
b 
Reproducibility  
of sample
b 
ID  (mV*sec)  (µg/g)  (µg/g) 
1  5.310  475  522 
2  5.438  515  514 
3  5.591  512  484 
4  5.410  503  505 
5  5.340  515  521 
6  5.411  525  500 
Mean  5.417  508  508 
SD  0.098  17.41  14.49 
RSD (%)  1.8  3.4  2.9 
95% CI(±)  0.1  18.3  15.2 
Overall statistical 
data (n=12) 
Mean  508   
SD  15.27   
RSD (%)  3.0   
95% CI(±)  9.7   
  MOX 
  Repeatability  
of standard
a 
Repeatability  
of sample
b 
Reproducibility  
of sample
b 
ID  (mV*sec)  (µg/g)  (µg/g) 
1  6.390  472  463 
2  6.037  462  467 
3  6.635  462  454 
4  6.141  473  476 
5  6.043  460  468 
6  6.514  472  456 
Mean  6.293  467  464 
SD  0.255  6.08  8.17 
RSD (%)  4.1  1.3  1.8 
95% CI(±)  0.3  6.4  8.6 
Overall statistical 
data (n=12) 
Mean  465   
SD  7.03   
RSD (%)  1.5   
95% CI(±)  4.5   
a…area of CPA; 
b…content of CPA. 
 
Solution stability  
The sample solutions were prepared by the spiking CPA at about 500 µg/g level into drug 
substances. The stability of the solutions for both drug substances was tested by recording 
the chromatograms freshly prepared and at different intervals with the gap of every one 
hour up to 12 hours at 27°C temperature. The stability of solution was determined by 
comparing the area of the freshly prepared sample solutions with 12 hours stability sample 
solutions, and the % difference in area was found to be 1.7 and 2.2 for NEV and MOX 86  P. K. S. R. Kothapalli et al.:   
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respectively. The results indicated that the sample solution was stable for up to 12 hours at 
27°C temperature.  
Comparison with GC method  
The LOD and LOQ values (0.10 & 0.37 µg mL
−1) of the newly developed IC method were 
compared with the LOD and LOQ values (3 & 7 ppm) of GC method reported by 
P.Raghuram et al [11].The results show that the present IC method is an alternative 
method for the determination of CPA and easy to handle with less cost of analysis. 
Conclusion 
This stability-indicating ion chromatography method results demonstrated that the method 
is specific, sensitive having LOD and LOQ (0.10, 0.37 µg mL
−1), linear (range: 0.37–1.5 µg 
mL
−1), precise, rugged and accurate. The method is promising for the analysis of CPA in 
NEV and MOX drug substances because of its enhanced sensitivity and simple sample 
handling with low cost of analysis. 
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